China Shineway Pharmaceutical Group Limited Cash Flow-to-Debt Ratio
China Shineway Pharmaceutical Group Limited cash flow-to-debt ratio. China Shineway Pharmaceutical Group Limited (C1S) has a Cash Flow-to-Debt Ratio of 0.07x as of June 2023, meaning its operating cash flow of €160.69 Million could theoretically repay 0% of its total liabilities (€2.26 Billion) in one year. Check C1S cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of China Shineway Pharmaceutical Group Limited (2013–2025)
Cash flow-to-debt ratio of China Shineway Pharmaceutical Group Limited from 2013 to 2025. Historical debt coverage capacity for China Shineway Pharmaceutical Group Limited across 13 annual periods. Check C1S capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
China Shineway Pharmaceutical Group Limited Cash Flow-to-Debt Ratio by Year (2013–2025)
China Shineway Pharmaceutical Group Limited cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for China Shineway Pharmaceutical Group Limited. For the full cash flow conversion analysis, see C1S cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.43x | €1.17 Billion | €2.72 Billion | ▲ +15.4% |
| 2024 | 0.37x | €963.13 Million | €2.57 Billion | ▲ +1.9% |
| 2023 | 0.37x | €932.63 Million | €2.54 Billion | ▼ -38.8% |
| 2022 | 0.60x | €1.11 Billion | €1.85 Billion | ▲ +11.1% |
| 2021 | 0.54x | €703.15 Million | €1.30 Billion | ▲ +20.0% |
| 2020 | 0.45x | €638.57 Million | €1.42 Billion | ▲ +65.6% |
| 2019 | 0.27x | €368.00 Million | €1.35 Billion | ▼ -50.7% |
| 2018 | 0.55x | €532.59 Million | €966.01 Million | ▼ -5.1% |
| 2017 | 0.58x | €490.65 Million | €844.16 Million | ▼ -33.6% |
| 2016 | 0.87x | €733.53 Million | €838.59 Million | ▲ +0.7% |
| 2015 | 0.87x | €744.71 Million | €857.13 Million | ▲ +14.0% |
| 2014 | 0.76x | €773.16 Million | €1.01 Billion | ▲ +91.9% |
| 2013 | 0.40x | €519.89 Million | €1.31 Billion | — |